The biotechnology company posted revenue of $98.9 million in the period. Regenxbio shares have fallen 24% since the beginning of the year.
News
- Regenxbio: 3Q Earnings Snapshot
- Otonomy: 3Q Earnings Snapshot
The biotechnology company posted revenue of $50,000 in the period. In the final minutes of trading on Wednesday, the company's shares hit $3.63.
- Bluebird: 3Q Earnings Snapshot
The biotechnology company posted revenue of $19.3 million in the period, which did not meet Street forecasts. Nine analysts surveyed by Zacks ...
- Anixa Biosciences – Consensus Indicates Potential 305.1% Upside
Anixa Biosciences has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy ...
- Debut of Chinese e-finance giant derailed by fear of risks
... company by sales volume, symbolized China's rebound and added to a string of smaller offerings by biotech and other new companies.